David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
David Steensma, MD, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Steensma says that patients who receive midostaurin, or any promising treatment in acute lymphoma, will likely still need to go on to recieve an allogeneic stem cell transplant. He adds that an allogeneic stem cell transplant is still a patient's best bet for immune effects in a tumor.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More